Achondroplasia Treatment for Your Child, Voxzogo, Yuviwel and the 2 FDA Decisions Coming in February

If your child has achondroplasia and their growth plates are still open, there are 2 FDA-approved medicines to choose from today and a third that may arrive in early 2027. Voxzogo (vosoritide) is a shot under the skin every day, approved for children of any age. Yuviwel (navepegritide) is a shot once a week, approved from age 2. Infigratinib, a daily pill from BridgeBio, faces an FDA decision on February 4, 2027, and 24 days later, on February 28, the FDA decides whether Voxzogo moves from accelerated to full approval based on long-term data that BioMarin says includes adult height. In their main trials, each drug added roughly 1.5 to 1.7 centimeters of growth a year over placebo. Whether that adds up to a taller adult, or fewer of the medical problems that come with achondroplasia, is the question February starts to answer.

Picture the routine that Voxzogo families have lived with since 2021. Around the same time every evening, a parent mixes powder and sterile water in a small vial, checks that their child has eaten, and makes sure they drank about a cup of fluid in the past hour, because the label asks for both to lower the chance of a dip in blood pressure. Then a shot under the skin. Then the same thing tomorrow, 365 times a year, for as long as the child is still growing.

That routine is what changed in February 2026, when the FDA approved Yuviwel as a once-weekly shot, and it is what BridgeBio hopes to change again with a capsule that can be opened and sprinkled on food. The growth numbers from the 3 trials look close, so for many families the real decision comes down to needles, age, side effects and what the child will tolerate. This guide lays those out from the FDA labels and the published trial.

Voxzogo vs Yuviwel vs Infigratinib for Achondroplasia at a Glance

Those 3 marks come from 3 separate placebo-controlled trials that enrolled children of different ages and measured growth over 52 weeks each. No trial has put any of these drugs against another, so the small gaps between them do not show that one works better. A head-to-head trial is now enrolling, covered in the trials section below.

Nearly every case of achondroplasia comes from the same change in one gene, FGFR3. The gene makes a receptor that works like a brake on the growth plates, the strips of cartilage near the ends of the long bones where growth happens. In achondroplasia that brake is stuck partly on.

Voxzogo and Yuviwel are both versions of CNP, a natural hormone that pushes back against the brake's signal inside the growth plate cells. Voxzogo is short-acting, which is why it is given daily. Yuviwel is CNP attached to a slow-release carrier that lets the dose last a week. Infigratinib works one step earlier, by blocking the overactive FGFR3 receptor itself, and it is swallowed instead of injected.

Voxzogo for Achondroplasia, the Daily Shot Approved in 2021

The FDA approved Voxzogo on November 19, 2021 for children 5 and older and widened it on October 20, 2023 to children of any age whose growth plates are still open. The approval rests on a 52-week trial of 121 children aged 5 to 14. Children on Voxzogo grew 1.57 centimeters a year more than children on placebo, a result with less than a 1 in 10,000 chance of being a fluke (Voxzogo FDA label).

Injection site reactions were common on both the drug and the placebo, because children in both groups got a shot every day. Redness at the shot site was reported in 75% of children on Voxzogo and 69% on placebo, swelling in 62% against 36%, and vomiting in 27% against 20%. A short drop in blood pressure was recorded in 13% of children on Voxzogo and 5% on placebo, which is the reason for the food and fluid rule and the only warning on the label.

One more Voxzogo story made the trade press this year. In March 2026 BioMarin stopped dosing and enrollment in 3 Phase 2 studies of Voxzogo in other short-stature conditions (Turner syndrome, SHOX deficiency and ACAN deficiency) after several cases of slipped capital femoral epiphysis, a hip problem in which the top of the thighbone slips out of place, were reported in 2 studies run by outside investigators, Fierce Pharma reported. BioMarin said no cases had been seen in its own studies in those conditions or among the more than 5,000 children treated with Voxzogo for achondroplasia.

Yuviwel for Achondroplasia, the Weekly Shot Approved in February 2026

Ascendis Pharma's Yuviwel was approved on February 27, 2026 for children 2 and older. In ApproaCH, the trial behind the approval, 84 children aged 2 to 12 who had never been treated grew 5.9 centimeters in a year on Yuviwel and 4.4 centimeters on placebo, a difference of 1.5 centimeters (Yuviwel FDA label).

The label breaks that result down by age in a way parents of toddlers will want to see. Children under 5 gained 1.0 centimeter a year over placebo, and children 5 and older gained 1.8. The label reports these as subgroup results and does not explain the gap, so treat it as a question for your doctor rather than a reason to wait or to rule Yuviwel out.

Across the 2 placebo-controlled Yuviwel trials, vomiting was reported in 21% of children on the drug and 14% on placebo, shot site reactions in 19% against 14%, pain in the arms or legs in 12% against 7%, and nausea in 6% against none. Extra hair growth, either at the injection site or on the limbs, back or shoulders, was reported in 2 of 68 children (3%) and none on placebo, and the label advises rotating the injection site each week. Yuviwel's only warning is the same low blood pressure caution, which the label bases on what was seen with daily CNP rather than on its own trials.

Two practical differences rarely make the headlines. Yuviwel's label does not ask for a meal and a drink before each shot, as Voxzogo's does, a point the Pediatric Endocrine Society's review of the drug also made. Its label lets a family give the weekly dose up to 2 days early or late, so a weekend trip or a sick day does not mean a missed dose. Yuviwel is not recommended for children with moderate or severe kidney impairment.

Infigratinib, the Achondroplasia Pill Facing an FDA Decision on February 4th

On October 6, 2026 BridgeBio announced that the FDA had accepted its application for infigratinib with priority review and set a decision date of February 4, 2027. If approved, it would be the first pill for achondroplasia. In PROPEL 3, 114 children aged 3 to 17 took a daily capsule or a placebo for 52 weeks. BridgeBio reports that children on infigratinib grew 1.74 centimeters a year more than on placebo in the trial's main analysis, and 2.10 centimeters more when the simple averages are compared. The results were published in the New England Journal of Medicine on June 28, 2026.

On safety, BridgeBio reports no discontinuations and no serious side effects related to the drug, and 3 cases (4%) of high blood phosphate that were mild, caused no symptoms and needed no dose change. Doctors watch phosphate with drugs in this family because blocking FGFR receptors can raise it. The company also reports better body proportions in children younger than 8 and better arm span, though the proportion result came from an exploratory analysis, one that the trial was not designed to prove.

“What matters is that individuals and families have meaningful choices.”

Michael Hughes, Little People of America, in BridgeBio's October 6, 2026 announcement

That line is worth sitting with. Some families choose no growth treatment at all, and Little People of America framed the infigratinib news around families having choices rather than around height. This guide lays out the options without assuming which one is right for your child.

February 2027, 2 Achondroplasia FDA Decisions and the First Look at Adult Height

Much of the trade press coverage of these drugs has been written for investors, as a sales contest between BioMarin, Ascendis and BridgeBio. For a family, the 2 February dates matter for a different reason.

February 4th is the pill. If the FDA approves infigratinib, families get a choice that involves no needles at all, and the label will spell out which ages it covers, how it is taken and what monitoring it needs. February 28th is the bigger scientific moment. BioMarin's application to convert Voxzogo to full approval, accepted by the FDA on July 13, 2026, rests on long-term data from 3 ongoing studies that BioMarin says include adult height, along with body proportions and arm span. If the FDA agrees, BioMarin says Voxzogo would be the first achondroplasia drug to move from accelerated to full approval.

Body proportions, and why 2 companies each claim a first

Height is not the only thing families ask about. Many care as much about arm length, which affects reaching and self-care, and about how the legs grow relative to the trunk. Both BridgeBio and BioMarin now report better body proportions, and the way each one measured it explains why both can describe their result as a first.

A lower upper-to-lower ratio means the legs grew more relative to the head and trunk. The 2 numbers cannot be lined up against each other, because one comes from 1 year of a randomized trial and the other from 4 years of treatment compared with untreated children. For Yuviwel, the Pediatric Endocrine Society's review reported no significant difference in this ratio in the ApproaCH trial at 1 year.

Questions to Ask Your Child's Doctor About Achondroplasia Treatment

Every one of these medicines is a long commitment, so it helps to walk into the appointment with specific questions rather than a general one about which drug is best.

Achondroplasia Clinical Trials Near Me, Enrolling at US Sites

ASPEN (NCT07441876) is the first trial to put 2 achondroplasia drugs head to head. BioMarin is comparing an experimental weekly shot called BMN 333 against its own daily Voxzogo in children aged 2 to 17, at 9 US sites. Ascendis is testing Yuviwel in infants from birth to age 2 against placebo (NCT06079398), and BridgeBio is testing infigratinib in children under 3 (NCT07169279), each at 3 US sites. Tyra Biosciences is running BEACH301 (NCT06842355), a Phase 2 study of an experimental drug called TYRA-300 in children aged 3 to 10, at 12 US sites.

You can also see which of these trials has a site nearest your home on our achondroplasia trials near me page, and sign up on the infigratinib decision page for an email the day the FDA acts. The Yuviwel drug page has the full label summary.

Achondroplasia Treatment Questions Parents Ask